Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Comparative Evaluation of Pharmacokinetics and Immunogenicity.

NCT: NCT06918587 · COMPLETED

NCT IDNCT06918587
StatusCOMPLETED
Start Date2024-09-05
Completion2025-05-25

Brief Summary

The Goal of these study is to evaluate and To compare the pharmacokinetics (PK) of the Test product (T) getting administered through prefilled syringe with on-body injector with Reference product as prefilled syringe following a single 6 mg dose administered through subcutaneous route in healthy adult Human subjects. Subjects safety and immunogenicity will also be evaluated during these study as follows Safety - monitoring the adverse events , vitals signs, ECG, laboratory parameters, and injection site assessment. Immunogenicity assessment- detection of ADA (Anti-PEG antibody levels ) and Nab (Neutralizing antibodies) will be done pre-dose and post dose on day 15 of each period.

Frequently Asked Questions

What is A Comparative Evaluation of Pharmacokinetics and Immunogenicity.?

A Comparative Evaluation of Pharmacokinetics and Immunogenicity. is a clinical trial registered under NCT06918587. Current status: COMPLETED.

What is the status of NCT06918587?

The current status of NCT06918587 (A Comparative Evaluation of Pharmacokinetics and Immunogenicity.) is: COMPLETED.

When did A Comparative Evaluation of Pharmacokinetics and Immunogenicity. start?

A Comparative Evaluation of Pharmacokinetics and Immunogenicity. started on 2024-09-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.